Regeneron insists its mAb fastest solution for Ebola
This article was originally published in Scrip
Executive Summary
Although it's well behind other companies, like Tekmira, Mapp Biopharmaceutical and Chimerix, in producing a drug against the deadly Ebola virus, which has now infected more than 14,000 people, killing greater than 5,100, Regeneron Pharmaceuticals on 12 November said using its monoclonal antibody (mAb) technology, it could have a drug candidate by year-end, with "robust quantities" of the product available for clinical testing a few months later.